



Supplemental Figure 1. Immunohistochemistry and H&E staining of WRJ388 tumors from the control group and the experimental group. The whole lung was dissected from nude mice with subcutaneous WRJ388 tumors. 5- μ m-thick formalin-fixed paraffin-embedded mouse tumor lung sections were used for H&E or TTF-1 IHC analyses. These samples were blinded and analyzed by a lung cancer pathologist (G. Sica). Red squares and black arrows indicated the location of lung adenocarcinoma metastasis in H&E slides at 2x or 10x magnification, respectively.



Supplemental Figure 2. Leflunomide dose-response in WRJ388 cells isolated from a leflunomide-resistant subcutaneous tumor. Leflunomide treatment significantly attenuated the growth of WRJ388 cells *in vivo* initially, but tumor growth resumed in the treated mice from day 22-24 (Figure 6B), and tumor number 9 (Figure 6D, bottom row) had the most significant growth. Cancer cells were isolated from this tumor and treated with leflunomide using SRB assay similar to the ones described in Figure 5B to determine leflunomide dose-response at Days 2 and 4.



Supplemental Table 1. Leflunomide treatment of HeLa xenograft

Table 1A. Log (tumor volume) across experiment groups at different time points

Days	Group	Mean (Std.Err)	p-value	Adjusted P-value*
0	control	4.879 (0.131)	0.115	0.575
0	treatment	4.571 (0.131)	.	
3	control	5.12 (0.12)	<.001	<0.005
3	treatment	4.44 (0.12)	.	
6	control	5.361 (0.113)	<.001	<0.005
6	treatment	4.309 (0.113)	.	
12	control	5.844 (0.115)	<.001	<0.005
12	treatment	4.048 (0.115)	.	
21	control	6.567 (0.152)	<.001	<0.005
21	treatment	3.656 (0.152)	.	

*p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 1B. Xenograft growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	-0.044 (0.008)	<.001
Growth Rate - Control	0.08 (0.008)	.

Table 1C. Analysis of final tumor weight

Level	N	Mean	Median	ANOVA P-value	Kruskal-Wallis P-value
Control	9	0.38	0.22	0.004	<0.001
Treatment	9	0.02	0.01		

Table 1D. Animal weight across experiment groups at different time points

Days	Group	Mean (Std.Err)	p-value	Adjusted P-value*
0	control	20.814 (0.499)	0.327	0.999
0	treatment	20.101 (0.499)	.	
3	control	21.026 (0.485)	0.239	0.999
3	treatment	20.186 (0.485)	.	
6	control	21.237 (0.478)	0.172	0.86
6	treatment	20.272 (0.478)	.	
12	control	21.661 (0.48)	0.092	0.46
12	treatment	20.442 (0.48)	.	
21	control	22.366 (0.534)	0.045	0.225
21	treatment	20.727 (0.534)	.	

*p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 1E. Animal weight growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	0.028 (0.018)	0.099
Growth Rate - Control	0.071 (0.018)	.

Supplemental Table 2. Leflunomide treatment of H460-xenografts

Table 2A. Log (tumor volume) across experiment groups at different time points

Day	Group	Mean (Std.Err)	p-value	Adjusted P-value*
0	Control	4.126 (0.2)	0.669	0.999
0	Treatment	4.003 (0.2)	.	.
4	Control	4.824 (0.194)	0.266	0.999
4	Treatment	4.508 (0.194)	.	.
9	Control	5.696 (0.191)	0.054	0.324
9	Treatment	5.139 (0.191)	.	.
14	Control	6.568 (0.191)	0.009	0.054
14	Treatment	5.769 (0.191)	.	.
18	Control	7.266 (0.194)	0.002	0.012
18	Treatment	6.274 (0.194)	.	.
23	Control	8.138 (0.201)	<.001	<0.006
23	Treatment	6.905 (0.201)	.	.

*p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 2B. Xenograft growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	0.126 (0.005)	<.001
Growth Rate - Control	0.174 (0.005)	.

Table 2C. Analysis of final tumor weight

Level	N	Mean	Median	ANOVA P-value	Kruskal-Wallis P-value
Control	10	2.78	3.05	<.001	0.004
Treatment	10	1.00	0.88		

Table 2D. Animal weight across experiment groups at different time points

Day	Group	Mean (Std.Err)	p-value	Adjusted P-value*
0	Control	18.723 (0.403)	0.372	0.999
0	Treatment	19.245 (0.403)	.	.
4	Control	18.966 (0.391)	0.676	0.999
4	Treatment	19.201 (0.391)	.	.
9	Control	19.271 (0.383)	0.822	0.999
9	Treatment	19.147 (0.383)	.	.
14	Control	19.575 (0.384)	0.386	0.999
14	Treatment	19.093 (0.384)	.	.
18	Control	19.819 (0.39)	0.181	0.999
18	Treatment	19.05 (0.39)	.	.
23	Control	20.123 (0.406)	0.065	0.39
23	Treatment	18.996 (0.406)	.	.

*p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 2E. Animal weight growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	-0.011 (0.011)	<.001
Growth Rate - Control	0.061 (0.011)	.

Supplemental Table 3. Leflunomide treatment of LKB1-mutant PDX

Table 3A. Log (tumor volume) across experiment groups at different time points

Days	Group	Estimated Mean (Std.Err)*	p-value	Adjusted P-value**
0	Control	5.305 (0.109)	0.927	0.9990
0	Treated	5.32 (0.109)		
7	Control	5.749 (0.105)	0.063	0.3155
7	Treated	5.428 (0.105)		
14	Control	6.192 (0.104)	0.002	0.0104
14	Treated	5.536 (0.104)		
21	Control	6.636 (0.104)	<.001	0.0008
21	Treated	5.644 (0.105)		
28	Control	7.079 (0.107)	<.001	0.0001
28	Treated	5.753 (0.108)		

*the estimation is based on the linear mixed-effect model assuming a linear growth of tumor volume.

**This p-value is adjusted for multiple comparisons by Bonferroni method.

Table 3B. PDX growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	0.015 (0.002)	<.001
Growth Rate - Control	0.063 (0.002)	.

Table 3C. Analysis of final PDX tumor weight

Level	N	Mean (SD)	Median	ANOVA P-value	Kruskal-Wallis P-value
Control	5	1.42 (1.27)	0.89	0.093	0.009
Treatment	5	0.32 (0.16)	0.30		

Table 3D. Animal weight across experiment groups at different time points

Days	Group	Mean (Std.Err)	p-value	Adjusted P-value*
0	Control	24.047 (0.512)	0.010	0.051
0	Treated	26.468 (0.512)		
7	Control	24.307 (0.505)	0.020	0.099
7	Treated	26.377 (0.505)		
14	Control	24.567 (0.502)	0.042	0.209
14	Treated	26.286 (0.502)		
21	Control	24.828 (0.503)	0.091	0.455
21	Treated	26.194 (0.504)		
28	Control	25.088 (0.508)	0.196	0.982
28	Treated	26.103 (0.51)		

The estimation is based on the linear mixed-effect model assuming a linear growth of tumor volume. *p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 3E. Animal weight growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	-0.013 (0.007)	<.001
Growth Rate - Control	0.037 (0.007)	.

Supplemental Table 4. Univariate Association with Leflunomide treatment in GEMM

Covariate	Statistics	Level	Group		Parametric P-value*	Non-Parametric P-value**
			Cont N=10	Trt N=10		
Percentage Change of BLI from Day0	N		10	10	0.006	0.003
	Mean		129.08	32.36		
	Median		89.59	18.2		
	Min		55.69	5.92		
	Max		330.98	76.86		
	Std Dev		92.74	28.76		
Percentage Change of Animal Weight from Day0	N		10	10	0.151	0.096
	Mean		-0.13	-0.05		
	Median		-0.09	-0.02		
	Min		-0.34	-0.34		
	Max		0	0.07		
	Std Dev		0.11	0.11		
Lung Weight(g) at Day 44	N		10	10	0.021	0.023
	Mean		0.51	0.38		
	Median		0.51	0.36		
	Min		0.34	0.27		
	Max		0.78	0.63		
	Std Dev		0.14	0.1		

* The parametric p-value is calculated by ANOVA.

** The non-parametric p-value is calculated by the Kruskal-Wallis test.

Supplemental Table 5. Leflunomide treatment of WRJ388 subcutaneous tumor

Table 5A. Log (tumor volume) across experiment groups at different time points

Days	Group	Mean (Std.Err)	p-value	Adjusted P-value*
0	Control	5.003 (0.087)	0.808	0.999
0	Treatment	5.034 (0.092)		
2	Control	5.182 (0.085)	0.462	0.999
2	Treatment	5.09 (0.089)		
4	Control	5.361 (0.083)	0.089	0.999
4	Treatment	5.145 (0.087)		
7	Control	5.63 (0.08)	0.003	0.040
7	Treatment	5.229 (0.085)		
9	Control	5.81 (0.079)	<.001	0.004
9	Treatment	5.285 (0.084)		
11	Control	5.989 (0.079)	<.001	<.001
11	Treatment	5.34 (0.083)		
13	Control	6.168 (0.078)	<.001	<.001
13	Treatment	5.396 (0.083)		
15	Control	6.348 (0.079)	<.001	<.001
15	Treatment	5.452 (0.083)		
17	Control	6.527 (0.08)	<.001	<.001
17	Treatment	5.507 (0.084)		
19	Control	6.706 (0.081)	<.001	<.001
19	Treatment	5.563 (0.085)		
21	Control	6.886 (0.082)	<.001	<.001
21	Treatment	5.619 (0.087)		
23	Control	7.065 (0.084)	<.001	<.001
23	Treatment	5.675 (0.089)		
24	Control	7.155 (0.085)	<.001	<.001
24	Treatment	5.702 (0.09)		

*p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 5B. Xenograft growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	0.028 (0.003)	<.001
Growth Rate - Control	0.09 (0.003)	

Table 5C. Analysis of final tumor weight (g)

Group	Mean (Std.Err)	p-value
Treatment	0.0218(0.0954)	0.0002
Control	0.794 (0.3094)	

Table 5D. Animal weight across experiment groups at different time points

Days	Group	Mean (Std.Err)	p-value	Adjusted p-value*
0	Control	20.015 (0.337)	0.447	0.999
0	Treatment	19.633 (0.356)		
2	Control	20.014 (0.329)	0.556	0.999
2	Treatment	19.727 (0.347)		

4	Control	20.013 (0.323)	0.686	0.999
4	Treatment	19.82 (0.34)		
7	Control	20.011 (0.315)	0.913	0.999
7	Treatment	19.96 (0.332)		
9	Control	20.01 (0.311)	0.924	0.999
9	Treatment	20.054 (0.328)		
11	Control	20.009 (0.309)	0.763	0.999
11	Treatment	20.147 (0.326)		
13	Control	20.008 (0.309)	0.611	0.999
13	Treatment	20.241 (0.326)		
15	Control	20.007 (0.31)	0.478	0.999
15	Treatment	20.334 (0.327)		
17	Control	20.006 (0.312)	0.366	0.999
17	Treatment	20.428 (0.329)		
19	Control	20.005 (0.316)	0.277	0.999
19	Treatment	20.521 (0.333)		
21	Control	20.004 (0.321)	0.209	0.999
21	Treatment	20.615 (0.339)		
23	Control	20.003 (0.328)	0.157	0.999
23	Treatment	20.708 (0.346)		
24	Control	20.003 (0.332)	0.137	0.999
24	Treatment	20.755 (0.35)		

*p-value is adjusted for the multiple comparisons by Bonferroni method.

Table 5E. Animal weight growth rate across two experiment groups

Group	Mean (Std.Err)	p-value
Growth Rate - Treatment	0.047 (0.011)	0.003
Growth Rate - Control	-0.001 (0.011)	

Table 5F. The BLI signals (1×10^5) in the lung for both experiment groups

Statistics	Control (N=10)	Treatment (N=9)	Parametric p-value*
N	10	9	0.008
Mean	97.58	6.58	
Median	68.23	5.88	
Min	9.01	1.09	
Max	249.8	20.76	

*The parametric p-value is calculated by ANOVA (two-sample t-test for two-group comparison)